Home - Products - Others - Other Targets - Hepcidin-22 (human) trifluoroacetate salt

Hepcidin-22 (human) trifluoroacetate salt

CAS No. 342790-22-1

Hepcidin-22 (human) trifluoroacetate salt( ——— )

Catalog No. M41736 CAS No. 342790-22-1

Hepcidin-22 (human) is an inactive degradation product of hepcidin-25 that is present in the urine.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Hepcidin-22 (human) trifluoroacetate salt
  • Note
    Research use only, not for human use.
  • Brief Description
    Hepcidin-22 (human) is an inactive degradation product of hepcidin-25 that is present in the urine.
  • Description
    Hepcidin-22 (human) is an inactive degradation product of hepcidin-25 that is present in the urine.
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    342790-22-1
  • Formula Weight
    2436.08
  • Molecular Formula
    C99H151N29O25S9
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kroot JJ, et al. Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011 Dec;57(12):1650-69.?
molnova catalog
related products
  • (D-Arg2,Lys4)-Dermor...

    DALDA is a potent and highly selective μ-opioid receptor agonist with a Ki of 1.69 nM. DALDA shows antinociceptive and respiratory effects.

  • SEP-0371845

    SEP-0371845 is a biochemical.

  • FL118

    FL118 is a novel survivin inhibitor that inhibits cancer stem cell-like properties.FL118 is a novel camptothecin analog with anticancer activity that inhibits epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway, thereby inhibiting migration and invasion of human breast cancer cells.